TY - JOUR
T1 - The Epidemiological, Clinical, Mycological, and Pathological Features of Rhino-cerebral Mucormycosis
T2 - A Systematic Review
AU - Salehi, Mohammadreza
AU - Mahmoudi, Shahram
AU - Rezahosseini, Omid
AU - Hashemi, Seyed Jamal
AU - Ahmadikia, Kazem
AU - Aala, Farzad
AU - Khajavirad, Nasim
AU - Alijani, Neda
AU - Izadi, Alireza
AU - Getso, Muhammad Ibrahim
AU - Abdollahi, Alireza
AU - Salami, Arezoo
AU - Khatami, Seyedeh Rana
AU - Adibimehr, Alireza
AU - Hedayat Yaghoobi, Mojtaba
AU - Sabahi, Mohammadmahdi
AU - Pazooki, Behshad
AU - Yazdi, Farhad
AU - Zebardast, Jayran
AU - Saifi, Arash
AU - Hasan Nezhad, Malihe
AU - Mardani, Masoud
AU - Khodavaisy, Sadegh
PY - 2022
Y1 - 2022
N2 - Cerebral mucormycosis (CM) is a life-threatening manifestation of mucormycosis, an angioinvasive fungal infection caused by Mucorales. We sought to systematically review all available case reports to describe epidemiologic features, clinical manifestations, predisposing factors, and diagnostic and treatment strategies of CM. A systematic search was conducted using a combination of the following keywords: "Mucor", "Zygomycetes", "mucormycosis", "cereb*", "brain", "central nervous system", and "intracranial", separately and in combination until December 31
st 2018. Data sources included PubMed, Scopus, EMBASE, Web of Science, Science Direct, and Proquest without limiting the time of publication. We included 287 articles corresponding to 345 cases of CM. Out of the 345 cases, 206 (60%) were male with a median age of 44 years; 130 (38%) were reported from North America; 87 (25%) from Asia; and 84 (24%) from Europe. The median time from onset of symptoms to presentation was 3-7 days (65/345, 65%). The highest mortality was observed among patients with diabetes mellitus (
P=0.003). Debridement of infected brain tissue was associated with improved survival in CM cases (OR 1.5; 95% CI 01.3-1.8;
P<0.0001). The use of liposomal amphotericin B (L-AMB) was significantly associated with patients' recovery (OR 2.09; 95% CI 1.2-3.4;
P=0.003). The combination of L-AMB and posaconazole (12.5%) was more effective than the monotherapy treatment of CM cases (
P=0.009). Clinicians should consider DM as an important risk factor for CM. Moreover, surgical debridement and antifungal combination therapy could be an effective approach in the management of CM patients.
AB - Cerebral mucormycosis (CM) is a life-threatening manifestation of mucormycosis, an angioinvasive fungal infection caused by Mucorales. We sought to systematically review all available case reports to describe epidemiologic features, clinical manifestations, predisposing factors, and diagnostic and treatment strategies of CM. A systematic search was conducted using a combination of the following keywords: "Mucor", "Zygomycetes", "mucormycosis", "cereb*", "brain", "central nervous system", and "intracranial", separately and in combination until December 31
st 2018. Data sources included PubMed, Scopus, EMBASE, Web of Science, Science Direct, and Proquest without limiting the time of publication. We included 287 articles corresponding to 345 cases of CM. Out of the 345 cases, 206 (60%) were male with a median age of 44 years; 130 (38%) were reported from North America; 87 (25%) from Asia; and 84 (24%) from Europe. The median time from onset of symptoms to presentation was 3-7 days (65/345, 65%). The highest mortality was observed among patients with diabetes mellitus (
P=0.003). Debridement of infected brain tissue was associated with improved survival in CM cases (OR 1.5; 95% CI 01.3-1.8;
P<0.0001). The use of liposomal amphotericin B (L-AMB) was significantly associated with patients' recovery (OR 2.09; 95% CI 1.2-3.4;
P=0.003). The combination of L-AMB and posaconazole (12.5%) was more effective than the monotherapy treatment of CM cases (
P=0.009). Clinicians should consider DM as an important risk factor for CM. Moreover, surgical debridement and antifungal combination therapy could be an effective approach in the management of CM patients.
UR - https://www.scopus.com/pages/publications/85128342052
U2 - 10.30699/ijp.2022.538690.2721
DO - 10.30699/ijp.2022.538690.2721
M3 - Review
C2 - 35463720
SN - 1735-5303
VL - 17
SP - 112
EP - 121
JO - Iranian journal of pathology
JF - Iranian journal of pathology
IS - 2
ER -